Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 11,964 Shares

20 Mar 2026, 08:48 by Doug Wharley · The Cerbat Gem

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) CEO Bobak Azamian sold 11,964 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $801,588.00. Following the sale, the chief executive officer owned 33,421 shares of the company’s stock, valued at $2,239,207. This represents a 26.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $66.75 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The firm has a market capitalization of $2.84 billion, a P/E ratio of -41.20 and a beta of 0.55. The business’s 50-day simple moving average is $69.36 and its 200-day simple moving average is $70.18.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The business had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. Equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Key Headlines Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published tighter FY‑2026 and quarterly EPS forecasts (e.g., FY2026 estimate moved toward a smaller loss), suggesting better-than-expected recovery potential and giving investors a fundamental bullish signal. Read More.
Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable (average recommendation ~“Moderate Buy”), so Lifesci’s view improves outlook but doesn’t represent unanimous conviction across Street. Read More.
Neutral Sentiment: Institutional ownership is high (around 90%), and several large funds recently increased positions—a stabilizing factor that can limit extreme volatility but also means big holders can move the stock via position changes. Read More.
Negative Sentiment: Significant insider selling: multiple Form 4s show the CEO, director William J. Link and several other insiders sold large blocks between March 16–19 (CEO sales ~11–12k shares on consecutive days; director sold 12,500 shares), which can trigger short‑term downward pressure and raises investor concern about near‑term liquidity or profit‑taking. Read More. | Read More.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TARS. Mizuho assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price on the stock. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. The Goldman Sachs Group restated a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Finally, Guggenheim upped their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $91.83.

Read Our Latest Stock Analysis on TARS

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TARS. TimesSquare Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals during the 3rd quarter valued at $15,898,000. Jennison Associates LLC lifted its holdings in Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock worth $154,790,000 after buying an additional 136,582 shares in the last quarter. TFG Asset Management GP Ltd lifted its holdings in Tarsus Pharmaceuticals by 40.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock worth $10,128,000 after buying an additional 71,530 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new position in Tarsus Pharmaceuticals in the 3rd quarter valued at about $14,264,000. Finally, Jump Financial LLC boosted its position in Tarsus Pharmaceuticals by 385.9% in the 2nd quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock valued at $9,606,000 after buying an additional 188,317 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.